Stem Cell Research Center Needs Overhaul, IOM Panel Says
By Marcia Frellick,
American Medical News
| 01. 08. 2013
[Quotes CGS's Marcy Darnovsky]
An Institute of Medicine review of California’s prominent center for stem cell research found organizational flaws and called for sweeping changes to reduce potential conflicts of interest.
The report praised the taxpayer-funded California Institute for Regenerative Medicine for its aggressive pace in awarding grants totaling $1.3 billion to 59 institutions, saying, “CIRM and those it has funded have set in motion a significant scientific enterprise.” However, the IOM found the center’s practices generate concerns about transparency and potential bias that could undermine support for the CIRM.
Reviewers found “far too many” CIRM board members represent organizations that were awarded grants or benefited from the grants. The majority of board members should be independent with no conflicting personal or professional interests, the committee said.
The CIRM definition of conflict of interest should be retooled to “include non-financial interests, such as the potential for personal conflicts of interest to arise from one’s own affliction with a disease or personal advocacy on behalf of that disease,” the report said (
iom.edu/~/media/Files/Report%20Files/2012/CIRM/CIRM_rb.pdf).
The IOM review called for the CIRM’s day-to-day operations to be...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...